---
schema_version: "secwatch.filing_event.v1"
accession: "0001193125-26-269557"
form_type: "8-K"
ticker: "LCTX"
cik: "0000876343"
company_name: "Lineage Cell Therapeutics, Inc."
filed_at: "2026-06-12T20:32:03+00:00"
generated_at: "2026-06-12T20:53:02.146925+00:00"
event_type: "other_material"
sentiment: "neutral"
materiality_score: 0.55
calibrated_materiality_score: 0.55
confidence: "high"
source: SEC EDGAR
---

# Lineage withdraws CIRM grant application for OPC1 SCI trial; annual meeting results disclosed

## Summary
- Withdrew CIRM CLIN2 grant application for OPC1 after receiving comments; says DOSED clinical study unaffected.
- Shareholders elected all seven director nominees, including Michael Mulroy, Dipti Amin, and Deborah Andrews.
- Ratified Baker Tilly as auditor for FY2026 (163.8M for, 0.7M against) and approved advisory say-on-pay (88.3M for, 2.6M against).

## SEC filing metadata
- accession: 0001193125-26-269557
- form_type: 8-K
- ticker: LCTX
- cik: 0000876343
- company_name: Lineage Cell Therapeutics, Inc.
- filed_at: 2026-06-12T20:32:03+00:00
- event_type: other_material
- sentiment: neutral
- materiality_score: 0.55
- calibrated_materiality_score: 0.55
- confidence: high
- sec_items: 5.07, 8.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/876343/000119312526269557/0001193125-26-269557-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/876343/000119312526269557/lctx-20260610.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001193125-26-269557
- JSON: https://secwatch.observer/filing/0001193125-26-269557.json
- Plain text: https://secwatch.observer/filing/0001193125-26-269557.txt

## Key facts
- Shareholder Votes
  Lineage Cell Therapeutics, Inc. shareholders approved Advisory vote on the compensation paid to the Company’s named executive officers at the 2026-06-10 meeting.
  - Proposal: say on pay
  - Outcome: passed
  - Meeting: 2026-06-10
  source text: 3. Shareholders approved, on an advisory basis, the compensation paid to the Company’s named executive officers, as set forth in the Proxy Statement, by the following votes:
  evidence_url: https://www.sec.gov/Archives/edgar/data/876343/000119312526269557/0001193125-26-269557-index.htm
- Shareholder Votes
  Lineage Cell Therapeutics, Inc. shareholders approved Election of seven nominees to the board of directors at the 2026-06-10 meeting.
  - Proposal: director election
  - Outcome: passed
  - Meeting: 2026-06-10
  source text: 1. Shareholders elected the seven nominees named below to the Company’s board to hold office until the Company’s 2027 annual meeting of shareholders and until their respective successors are duly elected and qualified by the following votes:
  evidence_url: https://www.sec.gov/Archives/edgar/data/876343/000119312526269557/0001193125-26-269557-index.htm
- Shareholder Votes
  Lineage Cell Therapeutics, Inc. shareholders approved Ratification of Baker Tilly US, LLP as independent registered public accounting firm for fiscal year ending December 31, 2026 at the 2026-06-10 meeting.
  - Proposal: auditor ratification
  - Outcome: passed
  - Meeting: 2026-06-10
  source text: 2. Shareholders ratified the appointment of Baker Tilly US, LLP as the Company’s independent registered public accounting firm for the fiscal year ending December 31, 2026 by the following votes:
  evidence_url: https://www.sec.gov/Archives/edgar/data/876343/000119312526269557/0001193125-26-269557-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.